These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30737073)

  • 1. PCSK9 inhibitors: A new improvement for health.
    Perelló Camacho E
    Clin Investig Arterioscler; 2019; 31(5):241-243. PubMed ID: 30737073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand.
    Page MM; Ekinci EI; Burnett JR; Hooper AJ; Reid N; Bishop W; Florkowski CM; Scott R; O'Brien RC; Watts GF
    J Clin Apher; 2021 Feb; 36(1):48-58. PubMed ID: 32911577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels.
    Sbrana F; Bigazzi F; Dal Pino B; Toma M; Ripoli A; Sampietro T
    Ther Apher Dial; 2019 Aug; 23(4):385-386. PubMed ID: 30311368
    [No Abstract]   [Full Text] [Related]  

  • 8. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 10. [PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].
    Corral P; Ruiz AJ
    Hipertens Riesgo Vasc; 2017; 34(4):176-183. PubMed ID: 28709786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B; Tselmin S; Bornstein SR; Julius U
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
    Razek O; Cermakova L; Armani H; Lee T; Francis GA; Mancini GBJ; Frohlich J; Brunham LR
    Can J Cardiol; 2018 Aug; 34(8):1004-1009. PubMed ID: 30056842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019.
    Ascaso JF; Civeira F; Guijarro C; López Miranda J; Masana L; Mostaza JM; Pedro-Botet J; Pintó X; Valdivielso P
    Clin Investig Arterioscler; 2019; 31(3):128-139. PubMed ID: 31130361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe familial hypercholesterolemia treatment].
    Vrablík M; Freiberger T; Bláha V; Češka R
    Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.